Changes in kynurenine metabolites in the gray and white matter of the dorsolateral prefrontal cortex of individuals affected by schizophrenia

Nico Antenucci,Giovanna D’Errico,Francesco Fazio,Ferdinando Nicoletti,Valeria Bruno,Giuseppe Battaglia,Giovanna D'Errico

DOI: https://doi.org/10.1038/s41537-024-00447-3

2024-02-28

Schizophrenia

Abstract:Alterations in the kynurenine pathway of tryptophan metabolism have been implicated in the pathophysiology of schizophrenia. Here, we performed an in-depth analysis of all metabolites of the kynurenine pathway, i.e., tryptophan (TRY), kynurenic acid (KYNA), L-kynurenine (KYN), 3-hydroxykynurenine (3-HK), anthranylic acid (ANA), 3-hydroxyanthranylic acid (3-HANA), xanthurenic acid (XA) and quinolinic acid (QUINA), in postmortem samples of the dorsolateral prefrontal cortex (DLPFC, Brodmann area 46, 9) of individuals affected by schizophrenia and non-schizophrenic controls. The analysis was carried out in the gray and white matter. Levels of KYN, 3-HK, ANA, and 3-HANA were significantly increased in both the gray and white matter of the DLPFC of individuals affected by schizophrenia, whereas levels of TRY, KYNA, and QUINA were increased exclusively in the white matter and remained unchanged in the gray matter. These increases in kynurenine metabolites did not correlate with age, sex, duration of the disease, and duration and type of antipsychotic medication. These findings suggest that the two major branches of the kynurenine pathway, i.e., the transamination of KYN into KYNA, and hydroxylation of KYN into 3-HK are activated in the white matter of individuals affected by schizophrenia, perhaps as a result of neuroinflammation, and support the evidence that abnormalities of the white matter are consistenly associated with schizophrenia.

psychiatry

What problem does this paper attempt to address?

The problem this paper attempts to address is the changes in metabolites of the kynurenine pathway of tryptophan metabolism in the dorsolateral prefrontal cortex (DLPFC) of patients with schizophrenia. Specifically, the study aims to comprehensively analyze the changes in all kynurenine pathway metabolites in the gray matter and white matter of the DLPFC in patients with schizophrenia compared to non-schizophrenic controls. Through this approach, the research not only helps to gain a deeper understanding of the neurobiological basis of schizophrenia but also potentially paves the way for the development of new therapeutic strategies. The study found that the levels of certain metabolites in the gray matter and white matter of patients with schizophrenia were significantly increased, and these changes were independent of age, gender, disease duration, and the type and duration of antipsychotic medication use.